These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 32134913)
1. NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome. Weuring WJ; Singh S; Volkers L; Rook MB; van 't Slot RH; Bosma M; Inserra M; Vetter I; Verhoeven-Duif NM; Braun KPJ; Rivara M; Koeleman BPC PLoS One; 2020; 15(3):e0219106. PubMed ID: 32134913 [TBL] [Abstract][Full Text] [Related]
2. New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome. Tiraboschi E; Martina S; van der Ent W; Grzyb K; Gawel K; Cordero-Maldonado ML; Poovathingal SK; Heintz S; Satheesh SV; Brattespe J; Xu J; Suster M; Skupin A; Esguerra CV Epilepsia; 2020 Mar; 61(3):549-560. PubMed ID: 32096222 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine. Zhang Y; Kecskés A; Copmans D; Langlois M; Crawford AD; Ceulemans B; Lagae L; de Witte PA; Esguerra CV PLoS One; 2015; 10(5):e0125898. PubMed ID: 25965391 [TBL] [Abstract][Full Text] [Related]
4. Behavioral Comorbidities and Drug Treatments in a Zebrafish Grone BP; Qu T; Baraban SC eNeuro; 2017; 4(4):. PubMed ID: 28812061 [TBL] [Abstract][Full Text] [Related]
5. CRISPRa-Mediated Upregulation of Weuring WJ; Dilevska I; Hoekman J; van de Vondervoort J; Koetsier M; van 't Slot RH; Braun KPJ; Koeleman BPC CRISPR J; 2021 Aug; 4(4):575-582. PubMed ID: 34406040 [TBL] [Abstract][Full Text] [Related]
6. Unexpected Efficacy of a Novel Sodium Channel Modulator in Dravet Syndrome. Anderson LL; Hawkins NA; Thompson CH; Kearney JA; George AL Sci Rep; 2017 May; 7(1):1682. PubMed ID: 28490751 [TBL] [Abstract][Full Text] [Related]
7. Genetic and Functional Differences between Duplicated Zebrafish Genes for Human Weuring WJ; Hoekman JW; Braun KPJ; Koeleman BPC Cells; 2022 Jan; 11(3):. PubMed ID: 35159264 [TBL] [Abstract][Full Text] [Related]
8. Microglia Mitigate Neuronal Activation in a Zebrafish Model of Dravet Syndrome. Brenet A; Somkhit J; Csaba Z; Ciura S; Kabashi E; Yanicostas C; Soussi-Yanicostas N Cells; 2024 Apr; 13(8):. PubMed ID: 38667299 [TBL] [Abstract][Full Text] [Related]
9. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Baraban SC; Dinday MT; Hortopan GA Nat Commun; 2013; 4():2410. PubMed ID: 24002024 [TBL] [Abstract][Full Text] [Related]
10. A selective Na Chow CY; Chin YKY; Ma L; Undheim EAB; Herzig V; King GF Biochem Pharmacol; 2020 Nov; 181():113991. PubMed ID: 32335140 [TBL] [Abstract][Full Text] [Related]
11. Activity of drugs and components of natural origin in the severe myoclonic epilepsy of infancy (Dravet syndrome). Berio A; Piazzi A Cent Nerv Syst Agents Med Chem; 2015; 15(2):95-8. PubMed ID: 25924876 [TBL] [Abstract][Full Text] [Related]
12. Role of the hippocampus in Nav1.6 (Scn8a) mediated seizure resistance. Makinson CD; Tanaka BS; Lamar T; Goldin AL; Escayg A Neurobiol Dis; 2014 Aug; 68():16-25. PubMed ID: 24704313 [TBL] [Abstract][Full Text] [Related]
13. Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy. Voskobiynyk Y; Battu G; Felker SA; Cochran JN; Newton MP; Lambert LJ; Kesterson RA; Myers RM; Cooper GM; Roberson ED; Barsh GS PLoS Genet; 2021 Jan; 17(1):e1009195. PubMed ID: 33411788 [TBL] [Abstract][Full Text] [Related]
14. Drug repurposing for Dravet syndrome in scn1Lab Sourbron J; Partoens M; Scheldeman C; Zhang Y; Lagae L; de Witte P Epilepsia; 2019 Feb; 60(2):e8-e13. PubMed ID: 30663052 [TBL] [Abstract][Full Text] [Related]
17. Altered Glycolysis and Mitochondrial Respiration in a Zebrafish Model of Dravet Syndrome. Kumar MG; Rowley S; Fulton R; Dinday MT; Baraban SC; Patel M eNeuro; 2016; 3(2):. PubMed ID: 27066534 [TBL] [Abstract][Full Text] [Related]
18. Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome. Rubinstein M; Westenbroek RE; Yu FH; Jones CJ; Scheuer T; Catterall WA Neurobiol Dis; 2015 Jan; 73():106-17. PubMed ID: 25281316 [TBL] [Abstract][Full Text] [Related]
19. Upregulation of Haploinsufficient Gene Expression in the Brain by Targeting a Long Non-coding RNA Improves Seizure Phenotype in a Model of Dravet Syndrome. Hsiao J; Yuan TY; Tsai MS; Lu CY; Lin YC; Lee ML; Lin SW; Chang FC; Liu Pimentel H; Olive C; Coito C; Shen G; Young M; Thorne T; Lawrence M; Magistri M; Faghihi MA; Khorkova O; Wahlestedt C EBioMedicine; 2016 Jul; 9():257-277. PubMed ID: 27333023 [TBL] [Abstract][Full Text] [Related]
20. Cell-Selective Adeno-Associated Virus-Mediated Tanenhaus A; Stowe T; Young A; McLaughlin J; Aeran R; Lin IW; Li J; Hosur R; Chen M; Leedy J; Chou T; Pillay S; Vila MC; Kearney JA; Moorhead M; Belle A; Tagliatela S Hum Gene Ther; 2022 Jun; 33(11-12):579-597. PubMed ID: 35435735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]